| Status: Partially superseded | |
AWMSG ADVICE PARTIALLY SUPERSEDED BY NICE GUIDANCE ISSUED MARCH 2019. Refer to TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
|
Medicine details |
|
| Medicine name | daratumumab (Darzalex®) |
| Formulation | 20 mg/ml concentrate for solution for infusion |
| Reference number | 3310 |
| Indication | In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | Non-submission |
| Status | Partially superseded |
| Ratification by Welsh Government | 07/08/2017 |
| Date of issue | 07/08/2017 |
| Date of last review | 08/08/2017 |
| NICE guidance | TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |